Literature DB >> 21145594

Anti-HLA-E mAb 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: Web-tools validate the immunogenic epitopes of HLA-E recognized by the antibodies.

Mepur H Ravindranath1, Tho Pham, Nadim El-Awar, Hugo Kaneku, Paul I Terasaki.   

Abstract

HLA-E shares several peptide sequences with HLA-class Ia molecules. Therefore, anti-HLA-E antibodies that recognize the shared sequences may bind to HLA-class Ia alleles. This hypothesis was validated with a murine anti-HLA-E monoclonal antibody (mAb) MEM-E/02, which reacted with microbeads coated with several HLA-B and HLA-C antigens. In this report, the hypothesis was reexamined with another mAb 3D12, considered to be specific for HLA-E. The antibody binding is evaluated by measuring mean fluorescence index [MFI] with Luminex Multiplex Flow-Cytometric technology. The peptide-inhibition experiments are carried out with synthetic shared peptides, most prevalent to HLA-E and HLA-Ia alleles. The results showed that mAb 3D12 simulated MEM-E/02 in recognizing several HLA-B and HLA-C antigens. Both 3D12 and MEM-E/02 did not bind to HLA-A, HLA-F and HLA-G molecules. As observed with MEM-E/02, binding of 3D12 to HLA-E is inhibited by the peptides sequences (115)QFAYDGKDY(123) and (137)DTAAQI(142). Decrease in binding of mAb 3D12 to HLA class Ia, after heat treatment of antigen coated microbeads, supports the contention that the epitope may be located at the outside of the "thermodynamically stable" α-helix conformations of HLA-E. Several sequence and structure-based web-tools were employed to validate the discontinuous epitopes recognized by the mAbs. The scores obtained by these web-tools distinguished the shared peptide sequences that inhibited the mAb binding to HLA-E. Furthermore, ElliPro web tool points out that both mAbs recognize the conformational discontinuous epitopes (the shared inhibitory peptide sequences) in the secondary structure of the HLA-E molecule. The study favors the contention that the domain of the shared inhibitory peptide sequences may be the most immunogenic site of HLA-E molecule. It also postulates and clarifies that amino acid substitution on or near the binding domains may account for the lack of cross reactivity of 3D12 and MEM-E/02 with HLA-A, HLA-F and HLA-G molecules.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21145594     DOI: 10.1016/j.molimm.2010.09.011

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  15 in total

1.  Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells.

Authors:  Richard Apps; Zhaojing Meng; Gregory Q Del Prete; Jeffrey D Lifson; Ming Zhou; Mary Carrington
Journal:  J Immunol       Date:  2015-03-09       Impact factor: 5.422

2.  A viral, transporter associated with antigen processing (TAP)-independent, high affinity ligand with alternative interactions endogenously presented by the nonclassical human leukocyte antigen E class I molecule.

Authors:  Elena Lorente; Susana Infantes; David Abia; Eilon Barnea; Ilan Beer; Ruth García; Fátima Lasala; Mercedes Jiménez; Carmen Mir; Antonio Morreale; Arie Admon; Daniel López
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

3.  Immunoglobulin (Ig)G purified from human sera mirrors intravenous Ig human leucocyte antigen (HLA) reactivity and recognizes one's own HLA types, but may be masked by Fab complementarity-determining region peptide in the native sera.

Authors:  M H Ravindranath; P I Terasaki; C Y Maehara; V Jucaud; S Kawakita; T Pham; W Yamashita
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

4.  Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.

Authors:  D Zhu; M H Ravindranath; P I Terasaki; T Miyazaki; T Pham; V Jucaud
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

5.  The differential impact of natural killer (NK) cell education via KIR2DL3 and KIR3DL1 on CCL4 secretion in the context of in-vitro HIV infection.

Authors:  I Lisovsky; G Isitman; A Tremblay-McLean; R Song; S DaFonseca; B Lebouchẻ; J-P Routy; J Bruneau; N F Bernard
Journal:  Clin Exp Immunol       Date:  2016-09-09       Impact factor: 4.330

6.  Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies.

Authors:  V Jucaud; M H Ravindranath; P I Terasaki; L E Morales-Buenrostro; F Hiepe; T Rose; R Biesen
Journal:  Clin Exp Immunol       Date:  2015-12-16       Impact factor: 4.330

7.  Response to Comment on "Influence of HLA-C expression level on HIV control".

Authors:  Richard Apps; Mary Carrington
Journal:  Science       Date:  2013-09-13       Impact factor: 47.728

8.  Suppression of blastogenesis and proliferation of activated CD4(+) T cells: intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal antibodies mimicking HLA-I reactivity of IVIg.

Authors:  M H Ravindranath; P I Terasaki; T Pham; V Jucaud; S Kawakita
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

9.  Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers.

Authors:  Mepur H Ravindranath; Vadim Jucaud; Soldano Ferrone
Journal:  J Immunol Methods       Date:  2017-08-04       Impact factor: 2.303

Review 10.  Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg.

Authors:  Mepur H Ravindranath; Fatiha El Hilali; Edward J Filippone
Journal:  Vaccines (Basel)       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.